Immutep Limited - American Depositary Shares (IMMP)

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Immutep announces results from Cohort B of the TACTI-003 Phase 2b trial. The combination of eftilagimod alfa and Merck's Keytruda shows a 35.5% ORR and 58.1% DCR in PD-L1 negative head and neck cancer patients, with no new safety concerns.

Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.

Immutep releases promising safety and efficacy data for 90mg eftilagimod alpha combined with paclitaxel in HR+/HER2- metastatic breast cancer. No serious adverse events were reported, and a 50% overall response rate was observed in the Phase 2/3 trial.

If you want to get well ahead of the market and don’t mind the risk factor, check out these stocks to triple your money.

If you don’t mind the immense risks associated with high-potential opportunities, these best penny stocks under $3 could be for you.

Immutep Limited's (NASDAQ: IMMP) lead candidate — a soluble LAG-3 protein, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) —

We're starting off Wednesday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning!

If you have the audacity to consider ultra-speculative opportunities, these ideas for best penny stocks under $3 might be appealing.

We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning!